AT-7519 trifluoroacetate
CAS No. 1431697-85-6
AT-7519 trifluoroacetate ( AT 7519 trifluoroacetate | AT7519 trifluoroacetate )
产品货号. M11831 CAS No. 1431697-85-6
一种有效的 CDK2 抑制剂,IC50 为 47 nM;还抑制 CDK1/4/5,IC50 为 190/67/18 nM,并对某些激酶(Aurora A、IR 激酶、MEK、PDK1、c-Abl,IC50>10 uM)表现出选择性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥392 | 有现货 |
|
| 5MG | ¥638 | 有现货 |
|
| 10MG | ¥1216 | 有现货 |
|
| 100MG | ¥5166 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AT-7519 trifluoroacetate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的 CDK2 抑制剂,IC50 为 47 nM;还抑制 CDK1/4/5,IC50 为 190/67/18 nM,并对某些激酶(Aurora A、IR 激酶、MEK、PDK1、c-Abl,IC50>10 uM)表现出选择性。
-
产品描述A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM); has antiproliferative activity against HCT116 cells with IC50 of 82 nM; exhibits good profile against cytochrome P450 isoforms (<30% inhibition at 10 uM for 1A2, 2D6, 3A4, 2C9, 2C19).Blood Cancer Phase 2 Clinical.
-
体外实验AT7519 (0-4 μM) TFA results in dose-dependent cytotoxicity with IC50s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 TFA overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) TFA induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) TFA inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells. AT7519 (250 nM) TFA inhibits cell cycle progression in human tumor cell lines. AT7519 TFA also induces apoptosis of human tumor cell lines. AT7519 (100-700 nM) TFA induces apoptosis in leukemia cell lines. AT7519TFAalso inhibits transcription in human tumor cell lines. Furthermore, AT7519 TFA inhibits RNA polymerase II and reduces antiapoptotic protein levels.
-
体内实验AT7519 TFA inhibits tumor growth in a human MM xenograft mouse model. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) TFA also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice.
-
同义词AT 7519 trifluoroacetate | AT7519 trifluoroacetate
-
通路Cell Cycle/DNA Damage
-
靶点CDK
-
受体CDK
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1431697-85-6
-
分子量496.2678
-
分子式C18H18Cl2F3N5O4
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESC1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl.C(=O)(C(F)(F)F)O
-
化学全称1H-Pyrazole-3-carboxamide, 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl-, 2,2,2-trifluoroacetate (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wyatt PG, et al. J Med Chem. 2008 Aug 28;51(16):4986-99.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
产品手册
关联产品
-
(S)-PF-06873600
(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.
-
ICEC 0942 hydrochlor...
ICEC 0942 (CT7001) 是一种有效的、选择性的、口服活性的 CDK7 抑制剂,IC50 为 41 nM,选择性是 CDK2 的 15 倍 (IC50=578 nM)。
-
CDK9-IN-7
CDK9-IN-7 (compound 21e) 是一种高效选择性的,具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干细胞特性。
021-51111890
购物车()
sales@molnova.cn

